FindTrial
Sign In

Pharmacogenomics of Treatment-Resistant Hypertension: A Study Comparing the Frequency of ENaC and NEDD4L Single Nucleotide Variants in Treatment-Resistant versus Controlled Hypertension

Pharmacogenomics of treatment resistant hypertension a study comparing the incidence of SNVs of genes ENaC and NEDD4L in treatment resistant hypertension with controlled hypertension - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/089971
Enrollment
480
Registered
2025-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Nil: Nil

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cases i.e. patients with Treatment resistant hypertension (TRH): Blood Pressure more than or equal to 130/80 mmHg and, Currently on at least three antihypertensive agents including diuretics and, Received the treatment for 3 months or more. 2. Controls i.e. patients with Controlled hypertension: Blood Pressure less than 130/80 mmHg and, Currently on three or less antihypertensive agents. 3. Willing to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Diagnosed CKD 2. Diagnosed secondary causes of hypertension 3. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
The frequency of the risk alleles and genotypes of the two selected SNVs (ENaC (rs80311498) and NEDD4L (rs4149601)) among patients with TRH and controlled hypertension, expressed as proportions and analyzed for statistical association.Timepoint: At baseline—

Secondary

MeasureTime frame
Mean age at presentation stratified by genotype & correlation analysis between SNV status & age of onset using appropriate statistical tests. Timepoint: At baseline;Distribution of the GRS among TRH & control patients & its predictive value in identifying TRH using logistic regression & ROC curve analysis.Timepoint: At baseline;Internal consistency (Cronbach s alpha), test retest reliability (intraclass correlation coefficient) & construct/criterion validity of the newly developed questionnaire in comparison with the Hill-Bone HBP Therapy Scale, measured in terms of correlation coefficients & predictive association with blood pressure control.Timepoint: At baseline;Stratified analysis of SNV prevalence & associations across gender (male/female) & geographic subgroups (urban/rural), identifying any significant interactions or modifiers.Timepoint: At baseline—

Countries

India

Contacts

Public ContactDr Ajay Prakash

PGIMER Chandigarh

vipul.bharati.pgi@outlook.com9987392304

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026